This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

XR303

Celtic Pharmaceutical Holdings L.P.

Drug Names(s): XR303

Description: XR303 is a radioimunotherapy product targeted at late-stage pancreatic and colon cancer (Projects XR303P and XR303C). The product comprises a super high affinity antibody, labelled with a radionuclide, 131Iodine. The antibody binds specifically to carcino-embryonic antigen (CEA), a marker which is widely expressed on solid tumours. The antibody can thus deliver a dose of radiation to the tumour that is sufficient to kill tumour cell whilst limiting damage to normal tissues.This antibody has been shown to bind to its target for extended periods.

Deal Structure: In September 2005, Celtic Pharmaceutical completed its takeover of Xenova Group plc and took full ownership of its drug candidate portfolio.


XR303 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug